The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)
Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have ‘vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high ris...
Principais autores: | Chen, Christopher L.H., Ikram, Kamran, Anqi, Qiu, Yin, Wong Tien, Venketasubramanian, Narayanaswamy, Chen, Annabel Shen-Hsing |
---|---|
Outros Autores: | School of Humanities and Social Sciences |
Formato: | Journal Article |
Idioma: | English |
Publicado em: |
2017
|
Assuntos: | |
Acesso em linha: | https://hdl.handle.net/10356/85129 http://hdl.handle.net/10220/43643 |
Registros relacionados
-
NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
por: Abdul Rashid, Anna Misya’il, et al.
Publicado em: (2021) -
NeuroAid™-II (MLC901) provides neuroprotection and enhances neuronal cell survival against kainic acid-induced excitotoxicity in vitro by activating the PI3K/AKT pathway
por: Anam Anjum, et al.
Publicado em: (2025-03-01) -
Cognitive dysfunction and general anesthesia: From pathogenesis to prevention and correction
por: A. M. Ovezov, et al.
Publicado em: (2016-11-01) -
Centella asiatica extract ameliorates deoxygenation-induced neurological dysfunction in zebrafish larvae
por: Ariani Ariani, et al.
Publicado em: (2024-05-01) -
NeuroAiD<sup>TM</sup>-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models
por: Anam Anjum, et al.
Publicado em: (2024-08-01)